Jazz Pharmaceuticals Director Anne O'Riordan Files Form 144 to Sell $3.36M in Common Stock

Overview

On October 8, 2026, Anne O'Riordan, a Director of Jazz Pharmaceuticals plc ($JAZZ), submitted a Form 144 filing declaring an intent to sell 14,687 ordinary shares with an aggregate market value of approximately $3.36 million.

Transaction Details

• Filer: Anne O'Riordan (Director)
• Security: Common Stock
• Shares Proposed for Sale: 14,687
• Aggregate Market Value: $3,356,713.85 (~$228.55 per share)
• Broker: Morgan Stanley Smith Barney LLC Executive Financial Services
• Source of Shares: Acquired on October 8, 2026, via stock option exercise from the issuer paid in cash.
• Past 3 Months Activity: The filer previously sold 1,692 shares on August 7, 2026, for gross proceeds of $435,673.08.

Market Impact & Significance

The proposed disposition represents approximately 0.02% of the company's 64,914,577 outstanding shares, presenting minimal market dilution or liquidity pressure. Because the transaction originates from a same-day option exercise, it likely reflects standard executive option monetization rather than an unhedged directional view on the company's prospects.